Advanced in Plasmacytoma

Dr. Tanya M. Wildes

Oncology | Hematology
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Advanced in Plasmacytoma
Unmc Physicians
Emile 42nd St, 
Omaha, NE 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Tanya Wildes is an Oncologist and a Hematologist in Omaha, Nebraska. Dr. Wildes is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Multiple Myeloma, Head and Neck Squamous Cell Carcinoma (HNSCC), Plasmacytoma, Smoldering Multiple Myeloma, and Bone Marrow Transplant. Dr. Wildes is currently accepting new patients.

Her clinical research consists of co-authoring 189 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MO
Hospital Affiliations
Bellevue Medical Center, LLC
The Nebraska Medical Center
Languages Spoken
English
American Sign Language
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellmark
  • HMO
  • POS
View 10 Less Insurance Carriers -

Locations

UNMC PHYSICIANS
Emile 42nd St, Omaha, NE 68198
Other Locations
UNMC PHYSICIANS
111 N 175th St, Omaha, NE 68118

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

26 Clinical Trials

Aging, Geriatric Syndromes and Clonal Hematopoiesis
Aging, Geriatric Syndromes and Clonal Hematopoiesis
Enrollment Status: Recruiting
Publish Date: April 25, 2025
Intervention Type: Genetic, Procedure, Other
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drugs: Mitomycin C, Pegfilgrastim
Study Phase: Phase 2
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other, Procedure
Study Drug: Itacitinib
Study Phase: Phase 1
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Radiation, Procedure, Biological, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial.
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug, Radiation, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Cetuximab
Study Phase: Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2024
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug, Biological
Study Drugs: Cetuximab, PD 0332991
Study Phase: Phase 1/Phase 2
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
A Single-Arm, Open-Label Phase I Clinical Trial of a JAK Inhibitor, Baricitinib, for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 1
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: March 10, 2022
Intervention Type: Biological, Drug
Study Phase: Phase 1
ESCALADARA: Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
ESCALADARA: Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma
Enrollment Status: Withdrawn
Publish Date: January 24, 2022
Intervention Type: Biological, Procedure
Study Drug: Dara-SC
Study Phase: Phase 2
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Lenalidomide Adherence in Older Adults: A Pilot Prospective Cohort Study of Oral Therapy for Multiple Myeloma
Lenalidomide Adherence in Older Adults: A Pilot Prospective Cohort Study of Oral Therapy for Multiple Myeloma
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Other
Optimizing Fall-risk Prediction in Older Adults With Cancer
Optimizing Fall-risk Prediction in Older Adults With Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Other
Adaptation of the STEPPING ON Fall Prevention Program for Older Adults Receiving Cancer Therapy
Adaptation of the STEPPING ON Fall Prevention Program for Older Adults Receiving Cancer Therapy
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Other
Study Phase: Not Applicable
In-Home Sensor Monitoring of Older Adults With Cancer: A Pilot Study
In-Home Sensor Monitoring of Older Adults With Cancer: A Pilot Study
Enrollment Status: Withdrawn
Publish Date: September 16, 2020
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Enrollment Status: Completed
Publish Date: November 15, 2019
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 16, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 25 Less Clinical Trials

189 Total Publications

Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL).
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL).
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 10, 2025
Similar Doctors
Advanced in Plasmacytoma
Dr. Stefano R. Tarantolo
Hematology Oncology | Oncology | Hematology
Advanced in Plasmacytoma
Dr. Stefano R. Tarantolo
Hematology Oncology | Oncology | Hematology

Oncology Hematology West, PC

7500 Mercy Rd, 
Omaha, NE 
 (3.1 miles away)
402-393-3110
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stefano Tarantolo is a Hematologist Oncology specialist and an Oncologist in Omaha, Nebraska. Dr. Tarantolo is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Tarantolo is currently accepting new patients.

Advanced in Plasmacytoma
Dr. Irfan A. Vaziri
Oncology | Hematology
Advanced in Plasmacytoma
Dr. Irfan A. Vaziri
Oncology | Hematology

Chi Health Clinic Specialty LLC

575 S 70th St, 
Lincoln, NE 
 (45.9 miles away)
Languages Spoken:
English, Sindhi, Sinhala, Urdu
See accepted insurances
Accepting New Patients

Irfan Vaziri is an Oncologist and a Hematologist in Lincoln, Nebraska. Dr. Vaziri is rated as a Distinguished provider by MediFind in the treatment of Plasmacytoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Familial Colorectal Cancer. Dr. Vaziri is currently accepting new patients.

Experienced in Plasmacytoma
Dr. Sarah A. Holstein
Hematology | Oncology
Experienced in Plasmacytoma
Dr. Sarah A. Holstein
Hematology | Oncology

Unmc Physicians

Emile 42nd St, 
Omaha, NE 
 (0.1 miles away)
402-559-4015
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients
Offers Telehealth

Sarah Holstein is a Hematologist and an Oncologist in Omaha, Nebraska. Dr. Holstein is rated as an Advanced provider by MediFind in the treatment of Plasmacytoma. Her top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Schnitzler Syndrome. Dr. Holstein is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wildes's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile